Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CD | O00329 | 3/20 | 0.37 |
| ▸ | CNR2 | P34972 | 9/20 | 0.37 |
| ▸ | PIK3R2 | O00459 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.36 |
| ▸ | SOS1 | Q07889 | 2/20 | 0.36 |
| ▸ | TPH1 | P17752 | 1/20 | 0.34 |
| ▸ | CHUK | O15111 | 1/20 | 0.33 |
| ▸ | PTPN11 | Q06124 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL716382 | 1.00 | PIK3CD (0.37) | PIK3CDCNR2PIK3R2KDM4EALDH1A1 | |
| SCHEMBL715637 | 0.90 | PIK3CD (0.37) | PIK3CDPIK3R2HRH4TPH1 | |
| SCHEMBL716761 | 0.90 | PIK3CD (0.37) | PIK3CDPIK3R2HRH4TPH1 | |
| SCHEMBL717289 | 0.88 | PIK3CD (0.40) | PIK3CDCNR2KDM4EALDH1A1SMN1; SMN2 | |
| SCHEMBL713501 | 0.88 | PIK3CD (0.40) | PIK3CDCNR2KDM4EALDH1A1SMN1; SMN2 | |
| SCHEMBL717891 | 0.85 | LRRK2 (0.39) | PIK3CDCNR2PIK3R2ALDH1A1HRH4 | |
| SCHEMBL717892 | 0.85 | LRRK2 (0.39) | PIK3CDCNR2PIK3R2ALDH1A1HRH4 | |
| SCHEMBL715761 | 0.85 | PIK3R2 (0.39) | PIK3R2HRH4TPH1 | |
| SCHEMBL715760 | 0.85 | PIK3R2 (0.39) | PIK3R2HRH4TPH1 | |
| SCHEMBL715265 | 0.84 | MAPT (0.42) | PIK3CDPIK3R2SMN1; SMN2SOS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4342878-A1 | ARGININE METHYLTRANSFERASE INHIBITOR AND USE THEREOF | Cytosinlab Therapeutics Co., Ltd. (CN) | 2024-03-27 | — | — | EP | claimed |
| EP-2403847-B1 | TRIAZINE DERIVATIVES AS KINASE INHIBITORS | UCB BIOPHARMA SPRL (BE) | 2016-03-02 | — | — | EP | claimed |
| US-8785393-B2 | Ophthalmic pharmaceutical compositions of DP2 receptor antagonists | PANMIRA PHARMACEUTICALS, LLC (US) | 2014-07-22 | — | — | US | claimed |
| US-8785628-B2 | Triazine derivatives as kinase inhibitors | UCB PHARMA, S.A. (BE) | 2014-07-22 | — | — | US | claimed |
| EP-4342878-A1 | ARGININE METHYLTRANSFERASE INHIBITOR AND USE THEREOF | Cytosinlab Therapeutics Co., Ltd. (CN) | 2024-03-27 | — | — | EP | disclosed |
| WO-2024054996-A1 | METHODS FOR THE TREATMENT OF DEPRESSION | AUTOBAHN THERAPEUTICS, INC. (US) | 2024-03-14 | — | — | WO | disclosed |
| EP-2403847-B1 | TRIAZINE DERIVATIVES AS KINASE INHIBITORS | UCB BIOPHARMA SPRL (BE) | 2016-03-02 | — | — | EP | disclosed |
| US-8785628-B2 | Triazine derivatives as kinase inhibitors | UCB PHARMA, S.A. (BE) | 2014-07-22 | — | — | US | disclosed |
| US-20120053167-A1 | Triazine Derivatives as Kinase Inhibitors | UCB PHARMA, S.A. (BE) | 2012-03-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120053167-A1 | Triazine Derivatives as Kinase Inhibitors | MAP3K15, PI4KA, MAP3K20 | PIK3CD 12/4885CNR2 1488/4885PIK3R2 93/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.